Abstract: Solid, stable formulations of therapeutic polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The therapeutic polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.
Type:
Application
Filed:
August 14, 2009
Publication date:
January 12, 2012
Applicant:
Ironwood Pharmaceuticals, Inc.
Inventors:
Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao
Abstract: A gold-coated iron oxide nanoparticle, method of making thereof, and method of using thereof is disclosed. The nanoparticle is substantially toxin free (making it clinically applicable), easily functionalized, and can serve as a contrast agent for a number of imaging techniques, including imaging a subject in at least two distinct imaging modes. Further, the nanoparticle is well-suited for therapeutic uses.
Type:
Application
Filed:
March 16, 2010
Publication date:
January 5, 2012
Inventors:
Zdravka Medarova, Anna Moore, Mehment Yigit
Abstract: Disclosed herein are processes for preparing implants that are particularly useful for thermally labile bioactive agents but can also generally be used with any bioactive agent. The disclosed processes avoid the use of heat during processing and therefore avoid heat induced degradation of the bioactive agent. Also disclosed are implants prepared by the disclosed methods.
Abstract: The present invention relates to a composition for manufacturing an orally disintegrating dosage form that is used to prevent a coating layer of an active substance which is formed in a predetermined size in order to mask a bitter taste or an unpleasant taste. A predetermined ratio of an excipient having lower hardness than the coated active substance and another excipient having higher hardness and larger particle size than the active substance are used as means for protecting the coating layer from being destroyed.
Type:
Application
Filed:
March 12, 2008
Publication date:
December 22, 2011
Inventors:
Mikyoung Hahn, Jin-Woo Choi, Dae-Hyeon Kim
Abstract: A method for labeling a UV-fluorescing substrate includes positioning a UV-fluorescing substrate adjacent to an inkjet material dispenser, and selectively jetting an edible, invisible, non-UV fluorescing ink onto the UV-fluorescing substrate with the inkjet material dispenser.
Type:
Grant
Filed:
September 22, 2004
Date of Patent:
December 20, 2011
Assignee:
Hewlett-Packard Development Company, L.P.
Abstract: Oral compositions, which are preferably chewable compositions, containing a peroxide source and a peroxide decomposition catalyst in a contactless manner liberate molecular oxygen in the oral cavity upon use by catalyzed decomposition of the peroxide source. The oral composition promotes oral health by providing a more aerobic environment for oral flora.
Abstract: Disclosed are nanoparticles for delivery of drugs and/or nutraceuticals that include a fibroin polypeptide and a drug or nutraceutical, wherein the nanoparticle has a diameter of about 1 nm to about 500 nm, and compositions of the nanoparticles. The nanoparticles may further include a chitosan, or a proteoglycan such as decorin. Also disclosed are methods of delivering a drug and/or nutraceutical to a subject that involve administering to the subject nanoparticles of the present invention. Also disclosed are methods of making the nanoparticles of the invention, and kits that include the nanoparticles of the invention.
Type:
Application
Filed:
November 20, 2009
Publication date:
December 15, 2011
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Anshu B. Mathur, Carmen N. Rios, Vishal Gupta, Abraham Aseh
Abstract: The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer that covers the surface of the inner core, wherein the inner core contains the medicament unstable to light and the outer layer contains a light-absorbing substance such as Red No. 2, Red No. 3, Yellow No. 4, Yellow No. 5, Blue No. 1, Red No. 3 aluminum lake, Yellow No. 4 aluminum lake, Yellow No. 5 aluminum lake, Blue No. 1 aluminum lake, Blue No. 2 aluminum lake, red ferric oxide, yellow ferric oxide, black iron oxide, carmine, or sodium copper chlorophyllin.
Abstract: The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions.
Type:
Application
Filed:
July 7, 2009
Publication date:
December 8, 2011
Applicant:
RATIOPHARM GMBH
Inventors:
Katrin Rimkus, Frank Muskulus, Sandra Brueck, Jana Paetz
Abstract: Hollow conjugated polyelectrolyte (HCPE) microcapsules contain at least one conjugated polyelectrolyte and at least one other polyelectrolyte of complementary charge and the microcapsule has a hollow core. The conjugated polyelectrolyte is a polymer with a multiplicity of charged repeating units where a portion of the charged repeating units form a pi-conjugated sequence. The complementary polyelectrolyte is a polymer with a complementary charged repeating unit to the charged repeating units of the conjugated polyelectrolyte. The HCPE microcapsules can be formed by successively coating a sacrificial core with alternating layers of complementary polyelectrolytes, at least one of which is a conjugated polyelectrolyte. The sacrificial core can be removed to form the hollow center of a HCPE microcapsule.
Type:
Application
Filed:
November 9, 2009
Publication date:
December 1, 2011
Applicant:
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.
Inventors:
KIRK S. Schanze, Motokatsu Ogawa, Jonathan R. Sommer, David G. Whitten, Thomas Corbitt
Abstract: A dosage form which is, in particular, sheet-like and rapidly disintegrating or soluble in an aqueous environment for rapid release of active ingredients in the oral cavity, in body orifices or in body cavities, where the dosage form comprises a matrix which comprises one or more water-soluble polymers as base substances, and comprises at least one active ingredient, is characterized in that the dosage form is provided with spaces or cavities which are present in the polymeric matrix and whose contents differ in terms of the state of aggregation from the matrix.
Type:
Application
Filed:
July 29, 2011
Publication date:
November 17, 2011
Applicant:
LTS LOHMANN THERAPIE-SYSTEME AG
Inventors:
Christian VON FALKENHAUSEN, Markus Krumme, Wolfgang Laux
Abstract: Self-breaking tablet and capsule formulations with a similar in vitro drug release profile for whole tablet and when broken and/or a bioequivalent drug release profile when taken whole or when broken are provided. Methods for production of these formulations and tablets and their administration are also provided.
Abstract: The present invention relates to a method for preparing a granulate of at least two active principles, including a step of applying said active principles to a solid particulate medium by dusting, said active principles not being plant extracts.
Abstract: The object of the invention is to provide a hard capsule that is excellent in stability even when filled with a solvent for dissolving a poorly soluble pharmaceutical active ingredient, and that has excellent mechanical strength in a low-humidity environment. The invention provides a hard capsule having a film containing (A) a polymer or copolymer obtained by polymerizing or copolymerizing at least one polymerizable vinyl monomer represented by Formula (1): H2C?C(R1)—COOR2 (1), wherein R1 represents hydrogen or methyl, and R2 represents hydrogen or C1-C4 alkyl, in the presence of polyvinyl alcohol and/or a derivative thereof; and (B) at least one compound selected from the group consisting of (B-1) polyhydric alcohols, (B-2) esters of polyhydric alcohols and C1--C5 carboxylic acids, and (B-3) esters of polyvalent carboxylic acids and C1-C5 alcohols.
Abstract: A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour.
Type:
Application
Filed:
June 29, 2011
Publication date:
November 10, 2011
Applicant:
ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD.
Abstract: An orally dissolvable thin film strip for the administration of the pharmaceutical active Propofol is formed by mixing a wet slurry of a water-soluble polymer, a polar solvent, the active Propofol, and optional additives. The slurry is then cast onto a substrate by slot die or knife-over-roll and is dried in an oven at a temperature that exceeds the boiling point of the solvent. The resulting dried thin film is cut into individual doses designed to administer 5 mg, 10 mg, or 20 mg of Propofol.
Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.
Abstract: It is described a gold nanoparticle coated with from two to five layers of a combination of a polyelectrolyte having amino functionality and a polyelectrolyte having sulfonic functionality, or with one single layer of said polyelectrolyte having amino functionality, preferably polyallylamine, or sulfonic functionality, preferably polystyrenesulfonic, characterized in that said nanoparticle comprises an outer layer of albumin. It is also described the process for its preparation, its use as carriers intended to cross blood-brain barrier and its use as medicament, in particular for treatment of neurodegenerative diseases, more in particular of diseases caused by protein aggregates, such as prion diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Also described are pharmaceutical compositions comprising said nanoparticle.
Type:
Application
Filed:
November 5, 2009
Publication date:
October 27, 2011
Inventors:
Giuseppe Antonio Legname, Silke Krol, Maria Fernanda Costa De Sousa
Abstract: A method for preparing drug in hemisphere-shaped dosage form. A high molecular weight solution containing the drug is prepared, and the solution is then dropped on a base material. The interface phenomena between the solution and different base materials makes the drop of high molecular weight solution containing the drug form a hemisphere-shape. After solidifying by cross-link or evaporation, the drug in hemisphere-shaped dosage form is obtained. The advantages of the preparation method are a simple and fast process, and simple operation. Applications of the method to prepare a drug in hemisphere-shaped dosage form are also provided.
Abstract: The present invention relates to a method for preparing a ferrite superparamagnetic nano particle engineered by magnesium doping, and a technique for applying it to hyperthermia cancer cell treatment and the heat shock protein (HSP) self-defense mechanism.
Abstract: This invention relates to a method for emulsion templating hollow silica-based particles. The particles are suitable for containing one or more active ingredients or for containing other smaller particles which may include one or more active ingredients. The emulsion templated particles can be formed from two or more silanes. The emulsion templated particles can also be formed from a silane and a compound that attaches a polymer on the shell of the hollow silica-based particles.
Type:
Application
Filed:
January 21, 2011
Publication date:
October 20, 2011
Inventors:
Daniel H. Traynor, Hao Xu, Henry G. Traynor, John Carson, Martin S. Flacks
Abstract: Disclosed herein are compositions, methods, and devices related to bilayer and monolayer membranes, their encapsulation in a hydrogel, and their formation. Methods of using the disclose compositions and devices are also disclosed.
Type:
Grant
Filed:
October 13, 2006
Date of Patent:
October 18, 2011
Assignee:
The Regents of the University of California
Inventors:
Jacob J. Schmidt, Noah Malmstadt, Tae-joon Jeon, Jason Poulos
Abstract: The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect.
Type:
Application
Filed:
December 2, 2010
Publication date:
October 13, 2011
Applicant:
Eurand Pharmaceuticals Limited
Inventors:
Luigi Mapelli, Flavio Fabiani, Luigi Boltri, Paolo Gatti, Mauro Serratoni, Roberto Cassanmagnago
Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.
Type:
Application
Filed:
May 10, 2011
Publication date:
October 6, 2011
Applicant:
Jagotec AG
Inventors:
Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
Abstract: The present invention relates to a method for preparation of an ultraviolet (UV)-curable inorganic-organic hybrid resin containing about or less than 4% volatiles and less than 30% organic residues. The UV-curable inorganic-organic hybrid resin obtained according to this method can be UV-cured within a markedly very short time and enables, upon curing, the formation of a transparent shrink- and crack-free glass-like product having high optical quality, high thermal stability and good bonding properties. In view of these properties, this hybrid resin can be used in various applications such as electro-optic, microelectronic, stereolithography and biophotonic applications.
Abstract: The present invention relates to oral taste masked pharmaceutical composition comprising ciprofloxacin or salts or esters thereof. It further relates to processes of preparing it.
Abstract: Formulations for systemic buccal delivery, in particular chewing gums, chewable tablets, orodispersible tablets, oromucosal preparations comprising sulpho-adenosyl-L-methionine (SAMe) which allows the absorption of the active principle through the oral mucosa are described.
Abstract: Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient.
Type:
Application
Filed:
June 10, 2011
Publication date:
September 29, 2011
Applicants:
DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.
Abstract: A composition comprising microspheres of a polymer matrix, having two different pharmaceutical actives having complementary, usually synergistic, activity in killing cells. The compositions have particular utility for treating tumours. Useful combinations are doxorubicin with rapamycin, irinotecan with ibuprofen, ibuprofen with doxorubicin and irinotecan with doxorubicin. The polymer matrix is preferably a crosslinked polyvinyl alcohol. The drugs may be included in the same microsphere, or microspheres each with an individual pharmaceutical agent may be mixed together. The microspheres are preferably used in chemoembolisation of tumours.
Type:
Application
Filed:
August 18, 2008
Publication date:
September 22, 2011
Applicant:
BIOCOMPATIBLES UK Limited
Inventors:
Andrew Lennard Lewis, Richard Edward John Forster, Mroa Voctoria Gonzalez-Fajardo, Yiqing Tang, Andrew Willam LLoyd, Gary John Phillips
Abstract: The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet.
Abstract: There are disclosed magnetic nanoparticles and embolisation compositions comprising the nanoparticles. There are also disclosed methods to make the nanoparticles and embolisation compositions and methods to deliver therapeutic agents to a subject.
Type:
Application
Filed:
March 4, 2011
Publication date:
September 8, 2011
Applicant:
Davis LLP
Inventors:
Yixiang Wang, Ken Cham-Fai Leung, Chris Hon Ki Cheng, Ling Qin
Abstract: A method of preparing a ceramic-resin composite material for bone repair, including preparing a predetermined amount of pH controlled substantially anhydrous coupling agent by mixing a liquid silane material, alcohol and organic acid, producing particulate bioactive glass having a desired particle size of less than about 53 mesh, measuring a desired quantity of the particulate bioactive glass into a mixing vessel, heating the mixing vessel and particulate bioactive glass to about 100 degrees Celsius, mixing the heated quantity of particulate bioactive glass and spraying a predetermined amount of substantially anhydrous coupling agent into the heated quantity of particulate bioactive glass to define an admixture, mixing the admixture for sufficient time to define a quantity of substantially evenly coated particles, heating the quantity of substantially evenly coated particles for sufficient time to evolve excess solvent therefrom, and incorporating the quantity of substantially evenly coated particles into a r
Abstract: Disclosed are pharmaceutical compositions, particularly oral dosage forms, which comprise two or more enteric coating materials, either as a coating or as part of a matrix dosage form, and methods of making and using the same. The compositions are characterized by having a sustained release profile at lower pH and an accelerated dissolution profile at higher pH.
Abstract: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.
Type:
Application
Filed:
May 6, 2011
Publication date:
August 25, 2011
Applicant:
Siegfried Generics International AG
Inventors:
Lambert Tillmann Röhrich, Beat W. Müller
Abstract: Various embodiments of methods for coating stents are described herein. One method is directed to a stent spraying apparatus calibration procedure. Another method is directed to obtaining a batch of stents where each stent has the same number of layers of coatings, and the same total amount of coating material.
Abstract: A system for coating a stent includes a device for weighing a stent, a device for aligning the stent with a stent support, a device for coating the stent, a device for drying the stent, and a device for inspecting the stent.
Type:
Grant
Filed:
June 15, 2007
Date of Patent:
August 23, 2011
Assignees:
Abbott Cardiovascular Systems Inc., ATS Automation Tooling Systems Inc.
Inventors:
Anthony S. Andreacchi, Yung-Ming Chen, Arnoldo M. Currlin, Antonio Garcia, Jason Van Sciver, Bryan D. Glenn
Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.
Abstract: The present invention relates to a coated dosage form having openings to expose the core material or an intermediate coating layer. The invention also relates to methods for manufacturing such coated dosage forms.
Type:
Application
Filed:
April 22, 2011
Publication date:
August 18, 2011
Inventors:
Christopher E. Szymczak, Irvin Matas Lash
Abstract: Methods are disclosed to improved adhesion of polymer coatings over polymer surfaces of stents which include plasma treatment, applying an adhesion promoting layer, surface treatments with solvents, and mechanical roughening techniques.
Type:
Grant
Filed:
December 10, 2007
Date of Patent:
August 16, 2011
Assignee:
Abbott Cardiovascular Systems Inc.
Inventors:
Yunbing Wang, Daniel A. Castro, Stephen D. Pacetti
Abstract: The invention relates to a coating composition for application to a veterinary pharmaceutical composition for oral administration, by a film coating method, comprising a powder appetising material a binder and a solvent. The invention further relates to a coating method by film coating of a solid veterinary pharmaceutical for oral administration and appetising medicaments for animals comprising a veterinary pharmaceutical composition and an appetising coating arranged around said composition, comprising an appetising material and a binder.
Abstract: The invention describes a coating composition comprising an effective amount of a water-soluble cellulose ether, a poly(N-vinyl pyrrolidone-co-vinyl acetate) copolymer, a film-forming agent based on D-glucose, and a plasticizer.
Abstract: The invention relates to the use of a coating composition for application to a solid veterinary pharmaceutical composition for oral administration for the prevention and/or treatment of cardiac insufficiency in animals, by a method of film coating comprising a powder appetizing material, a binder and a solvent. The invention further relates to a coating method by film coating of solid veterinary pharmaceutical compositions for oral administration for the prevention and/or treatment of cardiac insufficiency in animals and appetizing medicaments for animals comprising a solid veterinary pharmaceutical composition for oral administration for the prevention and/or treatment of cardiac insufficiency in animals made from pimobendan and an appetizing coating arranged around said composition comprising an appetizing material and a binder.
Abstract: The invention provides a pharmaceutical composition that can be used for efficient administration of low-molecular weight drugs and polymeric compounds such as peptides and proteins by methods other than injection, as well as a method for producing the composition. The pharmaceutical composition is for transmucosal administration and comprises (a) a drug having a positive or negative charge at a predetermined pH, (b) a pharmaceutically acceptable small particle and (c) a pharmaceutically acceptable surface-coating polymer capable of being electrically charged at the pH, wherein the surface of the small particle is coated by the surface-coating polymer, the drug is immobilized on the surface of the small particle via the surface-coating polymer, and a complex is formed by a noncovalent interaction between the small particle and the surface-coating polymer and a concurrent electrostatic interaction between the surface-coating polymer and the drug.
Type:
Application
Filed:
July 1, 2009
Publication date:
August 4, 2011
Applicant:
NITTO DENKO CORPORATION
Inventors:
Katsuyuki Okubo, Chieko Kitaura, Kenjiro Minomi, Elizabeth Pearson, Clive J. Roberts, Martyn C. Davies, Snjezana Stolnik-Trenkic, Lisbeth Illum
Abstract: The invention relates to a method for producing tablets comprising a polyallylamine polymer, comprising the steps (i) preparation of a polyallylamine polymer or pharmaceutically compatible salts thereof, optionally in a mixture with one or more pharmaceutical excipients; (ii) compaction to give a slug; (iii) granulation of the slug; and (iv) compression of the resulting granules to give tablets; and also to tablets, sachets and slugs comprising a compacted polyallylamine polymer. In addition, the invention relates to tablets comprising a polyallylamine polymer, in particular Sevelamer, with a bimodal pore size distribution.
Abstract: The invention relates to a dosage form for oral administration comprising a carrier tablet, wherein the carrier tablet is at least partially (preferably partially) covered by a film comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a pharmaceutically acceptable salt thereof, such as the mono-maleate salt thereof. In particular embodiments, the film, which at least partially covers the carrier tablet, comprises a stabiliser (e.g. citric acid), and/or a film former (e.g. hydroxypropylcellulose). The film is preferably present in a recess on the carrier tablet. The invention also relates to a method of producing said dosage form.
Type:
Application
Filed:
August 21, 2009
Publication date:
August 4, 2011
Inventors:
Allan James Clarke, Yu Li, Yinka Bunmi Ogunlana
Abstract: The invention relates to a method of marking a substrate comprising treating the substrate with a boron compound and a charrable agent, and, irradiating the areas of the substrate to be marked such that those areas change colour. Marked substrates obtainable by this method are also provided.
Type:
Application
Filed:
August 26, 2009
Publication date:
July 28, 2011
Inventors:
Martin Walker, Anthony Jarvis, Christopher Wyres, William Green